This image is not available for purchase in your country.

Kadcyla breast cancer drug

Kadcyla breast cancer drug

C020/8799

Rights Managed

This image is not available for purchase in your country.

Please contact your Account Manager if you have any query.

Credit

DR P. MARAZZI / SCIENCE PHOTO LIBRARY DR P. MARAZZI / SCIENCE PHOTO LIBRARY

Restrictions:

Editorial use only.

Caption

Kadcyla breast cancer drug. Packet of the anti-cancer drug trastuzumab emtansine, marketed by Roche under the trade name Kadcyla. This drug is an antibody-drug conjugate (ADC) with an antibody linked to a drug that kills the cancer cells targeted by the antibody. In this case, the conjugate is of trastuzumab (Herceptin) linked to the cytotoxic chemical mertansine (DM1). Herceptin targets the HER2 receptor in breast cancer. Trastuzumab emtansine was developed by Genentech and approved for use in the USA in 2013. Photographed in 2014.

Release details

Model release not required. Property release not available.

 {{ i.shot_duration ? i.shot_duration + ' ' : '' }}{{ i.shot_uhd ? '4K ' : i.hires ? 'HD ' : '' }}{{ i.spl_number }} R{{ i.license }}

  • Add to board
  • Similar {{ mediaType(i) }}